CITIIQ
CitiIQ (http://www.citiiq.com ) has applied its novel measurement standard to 1,170 global cities as an important step toward measuring the 4,000 cities of the world with a population over 100,000.
The 1,170 cities include those with populations greater than 500,000, the world’s country capitals, and the state capitals of Brazil, India China and the USA.
“Increasingly, the health and wellbeing of people depend upon the effectiveness of their city,” says Don Simmonds, Chief Executive Officer of CitiIQ. “Municipal leaders face immense challenges and benefit greatly when comprehensive, comparable data is available to guide their decisions.”
Most cities struggle to translate disparate data into actions that can make life better for their citizens. The CitiIQ measurement system is an objective assessment of the overall health and wellbeing of a city. It converts raw data into scores out of 100 so that city elements are readily compared within a given city, or with other cities around the world.
CitiIQ uses an evidence-based methodology to score 35 essential elements, or Considerations, within five prioritized Dimensions including Basic Needs, Competitiveness, Opportunity, Livability, and Destiny. Using an intuitive online dashboard, a city’s measurements are readily available to clients through a cloud-based annual subscription.
“The CitiIQ measurement helps immensely in understanding the factors that influence a city,” says Harry Loubser, Managing Director of Unashamedly Ethical based in Cape Town, South Africa. “It's value to municipal leaders is readily apparent but the ability to compare city to city across so much of the world is a powerful advantage. We can clearly identify where best practise has been applied, but also illuminate cities with the greatest needs.”
The CitiIQ system is easy to use, economical, and effective with no need to purchase new software or abandon existing metrics. Aligned with the United Nations Sustainable Development Goals, CitiIQ provides a practical way for a city to mark progress toward SDG achievement.
City Administrators appreciate the integration of economic, environmental, social and cultural infrastructure measures reflecting how a city actually functions. The algorithm normalizes data into a comparable, holistic picture of their city’s strengths and weaknesses bringing coherence and comparability to their operations and an ability to compare with other cities.
In April 2020 CitiIQ was selected by UN-Habitat to develop a COVID-19 Readiness and Responsiveness tracking site for more than 1,000 global cities. Data was often unavailable at a city level where the real battle is fought. The scoring reflects both how ready a city was for COVID-19 and how well they are responding to the pandemic. COVID-19 data is collected daily for the 1,000 cities supporting improve responses to the pandemic. Visit: https://unhabitat.citiiq.com/ .
About CitiIQ
CitiIQ is a comprehensive system that objectively measures the overall health and wellbeing of a city. Using an intuitive online dashboard style interface, a city’s measurements are made readily available to clients through a cloud-based annual subscription.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom